Baicalein decreases uric acid and prevents hyperuricemic nephropathy in mice
Metrics: PDF 1903 views | HTML 2244 views | ?
Xiaolu Meng1, Zhuo Mao2, Xin Li3, Dandan Zhong1, Min Li1, Yingli Jia1, Jing Wei2, Baoxue Yang1 and Hong Zhou1
1Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing, 100191, P.R. China
2Tianjin Key Laboratory for Modern Drug Delivery and High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, 300072, P.R. China
3Drug Clinical Trial Institution, The Affiliated Hospital of Qingdao University, Qingdao, 266003, P.R. China
Hong Zhou, email: email@example.com
Keywords: baicalein, hyperuricemia, uric acid, nephropathy, xanthine oxidoreductase
Received: January 06, 2017 Accepted: March 24, 2017 Published: April 07, 2017
Baicalein, a natural flavonoid, is structurally advantageous for binding to xanthine oxidoreductase. In our study, molecular docking analysis and Surface Plasmon Resonance revealed a direct interaction between baicalein and xanthine oxidoreductase. Moreover, 50 mg/kg/d baicalein treatment significantly suppressed the viability of xanthine oxidoreductase in hyperuricemia mouse model. The data showed that baicalein remarkably prevented renal dysfunction, ameliorated kidney fibrosis, alleviated epithelial-mesenchymal transition and oxidative stress in hyperuricemia mice. Thus, we concluded that baicalein executed a kidney-protection action in hyperuricemia and therefore may be used as a therapeutic alternative for hyperuricemic nephropathy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.